NARG1 (NMDA (N-methyl-δ-aspartate) receptor-regulated gene 1), also known as NATH (N-terminal acetyltransferase), TBDN100 (tubedown-1) or Ga19 (gastric cancer antigen Ga19), is a cytoplasmic protein that contains eight TPR repeats. NARG1 is expressed at high levels in dividing tissues such as bone marrow, testis and embryonal brain and it is overexpressed in papillary thyroid carcinomas. NARG1 interacts with ARD1 or ARD2 forming a complex that exhibits N-terminal (α) acetyltransferase activity. The complex interacts with ribosomal subunits functioning in cotranslational acetylation. During apoptosis, both NARG1 and ARD1 are cleaved by caspases which results in decreased acetyltransferase activity. Knockdown of NARG1 in HeLa cells leads to apoptosis, indicating that properly functioning NARG1 is essential for cell viability. In addition, this suggests NARG1 as a potential target in cancer therapy

N-alpha-acetyltransferase 15, NatA auxiliary subunit; Gastric cancer antigen Ga19; N-terminal acetyltransferase; NMDA receptor-regulated protein 1; Protein tubedown-1; Tbdn100; NAA15; GA19; NARG1; NATH; TBDN100

q9bxj9

Human,Mouse,Rat

WB

WB 1:500-1:1000

~ 101 kDa

Rabbit

This antibody detects endogenous levels of NARG1 protein.

Synthetic peptide, corresponding Human NARG1.

Polyclonal

Rabbit IgG

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

PBS with 0.02% sodium azide, 50% glycerol, pH7.2

1mg/ml

Store at 4℃ short term,and store at -20℃ long term. Avoid freeze-thaw cycles.